Drug intelligence / Profile preview

Dormifort

Development stage: Unknown
Lead developer: Sanifortpharma
Modality: Small Molecules
Administration: Oral

Overview

Dormifort is a dietary supplement developed by Sanifortpharma designed to support the complete sleep cycle, including falling asleep, staying asleep, and waking up refreshed. It is an oral herbal formulation containing extracts of valerian (*Valeriana officinalis*), lemon balm (*Melissa officinalis*), and linden blossom (*Tilia*). These plant-based active ingredients are traditionally used for their calming and sedative properties, believed to interact with GABAergic transmission in the brain to induce sleep and reduce insomnia symptoms. As a nutritional supplement, it is marketed for sleep induction and calming effects rather than as a regulated pharmaceutical drug.

Brand names: Dormifort

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on Dormifort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dormifort.

Explore the full profile